Laurus Labs Ltd

Laurus Labs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Laurus Labs Ltd

₹ 964 -0.65%
31 Oct 11:33 a.m.
lauruslabs.com BSE: 540222 NSE: LAURUSLABS
About

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership
position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing.
Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Key Points

Business Segments
1) Generic API (46% in 9M FY25 vs 41% in FY22): [1] [2] The company has one of the largest HiPotent API manufacturing capacities in India and is the world's leading third-party supplier of antiretroviral APIs. Its portfolio includes antiretrovirals, oncology, steroids, hormones, and cardiovascular APIs, serving global generic pharmaceutical companies. Segment revenue declined by 3% YoY in 9M FY25 due to ARV capacity reallocation towards high-yield, long-term business opportunities. [3] [1]

Website BSE NSE
  • Market Cap ₹ 52,023 Cr.
  • Current Price ₹ 964
  • High / Low ₹ 973 / 474
  • Stock P/E 76.1
  • Book Value ₹ 89.0
  • Dividend Yield 0.12 %
  • ROCE 9.15 %
  • ROE 7.45 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 19.5%

Cons

  • Stock is trading at 10.8 times its book value
  • Company has a low return on equity of 10.5% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE MidCap Nifty Pharma

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
1,576 1,545 1,381 1,182 1,224 1,195 1,440 1,195 1,224 1,415 1,720 1,570 1,653
1,127 1,141 1,095 1,015 1,037 1,014 1,198 1,024 1,045 1,130 1,300 1,187 1,250
Operating Profit 449 404 286 167 188 181 241 171 178 285 421 382 403
OPM % 28% 26% 21% 14% 15% 15% 17% 14% 15% 20% 24% 24% 24%
1 1 2 4 2 2 19 3 5 9 59 10 27
Interest 40 43 53 39 42 51 50 49 53 58 56 52 40
Depreciation 82 84 87 91 93 98 102 106 108 106 110 117 120
Profit before tax 328 278 147 41 54 35 107 18 23 131 312 224 270
Tax % 29% 27% 27% 30% 27% 27% 30% 34% 22% 31% 25% 28% 28%
233 203 105 27 37 23 75 13 20 93 233 162 194
EPS in Rs 4.33 3.77 1.91 0.46 0.69 0.43 1.40 0.23 0.37 1.71 4.33 3.02 3.61
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
1,160 1,327 1,778 1,905 2,056 2,292 2,832 4,814 4,936 6,041 5,041 5,554 6,358
951 1,126 1,415 1,497 1,642 1,935 2,266 3,262 3,512 4,448 4,261 4,499 4,867
Operating Profit 208 200 362 408 414 357 565 1,552 1,424 1,592 779 1,055 1,491
OPM % 18% 15% 20% 21% 20% 16% 20% 32% 29% 26% 15% 19% 23%
9 34 4 32 29 15 5 23 14 6 24 75 105
Interest 64 106 111 100 80 88 90 68 102 165 183 216 206
Depreciation 33 62 86 106 125 164 187 205 251 324 385 430 454
Profit before tax 121 67 169 234 237 120 294 1,301 1,084 1,109 236 484 937
Tax % 20% -2% 21% 19% 29% 22% 13% 24% 23% 28% 29% 27%
97 68 134 190 168 94 255 984 832 793 162 358 682
EPS in Rs 12.64 8.81 16.97 3.60 3.16 1.76 4.77 18.33 15.40 14.67 2.98 6.64 12.67
Dividend Payout % 0% 0% 2% 8% 9% 17% 10% 11% 13% 14% 27% 18%
Compounded Sales Growth
10 Years: 15%
5 Years: 14%
3 Years: 4%
TTM: 26%
Compounded Profit Growth
10 Years: 17%
5 Years: 5%
3 Years: -27%
TTM: 422%
Stock Price CAGR
10 Years: %
5 Years: 25%
3 Years: 27%
1 Year: 98%
Return on Equity
10 Years: 17%
5 Years: 18%
3 Years: 11%
Last Year: 7%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 15 16 16 106 106 106 107 107 107 108 108 108 108
Reserves 281 640 774 1,225 1,377 1,452 1,663 2,490 3,244 3,930 4,003 4,365 4,697
605 888 1,094 842 980 1,036 1,079 1,482 1,777 2,015 2,577 2,764 2,212
372 345 339 481 554 737 901 1,671 1,840 1,608 1,699 2,099 2,398
Total Liabilities 1,273 1,888 2,224 2,653 3,017 3,331 3,750 5,751 6,968 7,660 8,387 9,336 9,415
499 801 1,021 1,230 1,481 1,629 1,726 2,171 2,652 3,409 3,890 4,123 4,242
CWIP 116 110 70 143 163 110 67 362 813 551 423 458 541
Investments 0 7 7 3 3 3 3 3 31 50 124 233 261
658 970 1,126 1,277 1,369 1,589 1,953 3,214 3,472 3,651 3,950 4,521 4,371
Total Assets 1,273 1,888 2,224 2,653 3,017 3,331 3,750 5,751 6,968 7,660 8,387 9,336 9,415

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
121 -65 182 332 342 298 347 733 911 994 666 602
-312 -397 -312 -289 -384 -253 -221 -941 -914 -997 -822 -680
203 486 103 -54 42 -45 -128 255 30 -27 250 39
Net Cash Flow 12 24 -27 -10 1 -0 -1 47 27 -30 93 -39

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 61 78 91 109 101 113 102 99 100 96 120 132
Inventory Days 165 210 176 186 201 201 234 266 293 222 277 285
Days Payable 114 102 90 96 107 144 159 199 146 94 158 141
Cash Conversion Cycle 112 186 178 199 195 170 177 166 247 224 240 276
Working Capital Days 61 -0 19 3 -11 6 15 43 43 59 42 43
ROCE % 14% 16% 16% 14% 8% 14% 40% 26% 23% 7% 9%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
27.20% 27.20% 27.20% 27.20% 27.18% 27.18% 27.18% 27.18% 27.62% 27.62% 27.60% 27.60%
21.90% 22.42% 22.52% 24.03% 25.39% 25.98% 25.67% 26.08% 25.56% 25.51% 25.70% 26.17%
9.51% 9.74% 10.36% 11.01% 11.13% 11.78% 13.56% 13.05% 12.74% 11.78% 11.94% 11.72%
41.38% 40.64% 39.93% 37.75% 36.30% 35.07% 33.59% 33.69% 34.09% 35.09% 34.78% 34.52%
No. of Shareholders 4,23,9314,18,6154,17,9774,02,6403,82,8803,56,8303,24,0593,09,0632,92,2142,92,9052,80,2232,83,678

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls